Effets indésirables des traitements contre l’ostéoporose : comment les expliquer aux patient-e-s ? [Side effects of osteoporosis treatments: how to explain them to patients?]

Details

Ressource 1Request a copy Under embargo until 19/10/2024.
UNIL restricted access
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_0510C417447B
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Effets indésirables des traitements contre l’ostéoporose : comment les expliquer aux patient-e-s ? [Side effects of osteoporosis treatments: how to explain them to patients?]
Journal
Revue medicale suisse
Author(s)
Curraj E., Gonzalez Rodriguez E.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
19/04/2023
Peer-reviewed
Oui
Volume
19
Number
823
Pages
746-751
Language
french
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Abstract
Despite the effectiveness of osteoporosis treatments, fear of side effects reduces both their prescription by doctors, and their acceptance by patients. The most common side effects are benign and transient, such as flu-like symptoms after zoledronate infusion, or nausea and dizziness after teriparatide introduction. On the other hand, the dreaded osteonecrosis of the jaw is very rare and associated with known risk factors. Only vertebral fractures after stopping denosumab make this treatment a matter for experienced practitioners. Therefore, knowing the side effects of prescribed treatments and explaining them to patients is essential to promote adherence.
Keywords
Humans, Female, Bone Density Conservation Agents/adverse effects, Denosumab/adverse effects, Osteoporosis/chemically induced, Osteoporosis/drug therapy, Teriparatide/adverse effects, Zoledronic Acid/therapeutic use, Drug-Related Side Effects and Adverse Reactions, Osteoporosis, Postmenopausal/drug therapy, Osteoporotic Fractures, Diphosphonates/adverse effects
Pubmed
Create date
08/05/2023 12:49
Last modification date
18/11/2023 7:08
Usage data